Substance Abuse and Mental Health Services Administration (SAMHSA)
Resources and Tools
Harm reduction strategies and tools should be accessible to everyone – regardless of location, time, and/or experience.
Articles in this supplement focus on the global opioid crisis, including coverage of harm reduction approaches, health justice promotion, and lessons learned.
This month, the Department of Health and Human Services (HHS), through the Substance Abuse and Mental Health Services Administration (SAMHSA), announced three funding opportunities to strengthen mental health and substance use systems and services for people with or affected by HIV:
In Los Angeles, New York, Houston, Philadelphia, and Washington, D.C., a National Institutes of Health funded clinical trial, known as INTEGRA, is evaluating the efficacy of delivering integrated HIV and substance use disorder care via mobile clinics.
A recent study published in Drug and Alcohol Dependence found evidence for racial/ethnic disparities in buprenorphine distribution across the United States.
This Advisory offers guidance to providers and administrators in SUD treatment programs on screening clients for hepatitis A, hepatitis B, and hepatitis C infections, as well as action steps for the treatment and support of clients with a viral hepatitis infection and a SUD.
This Advisory highlights strategies and considerations for substance use disorder (SUD) treatment providers to integrate HIV services into their practice and effectively engage people with HIV in SUD treatment.
This publication, part of SAMHSA's Evidence Based Resource Guide series, addresses the co-occurrence of HIV and mental illness and/or SUD.